Suppr超能文献

基于微流控的外泌体分离和高灵敏度适配体外泌体膜蛋白检测用于肺癌诊断。

Microfluidic-based exosome isolation and highly sensitive aptamer exosome membrane protein detection for lung cancer diagnosis.

机构信息

Guangzhou Laboratory, Guangzhou, Guangdong Province, 510005, PR China.

Department of Thoracic Surgery, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, 430014, PR China.

出版信息

Biosens Bioelectron. 2022 Oct 15;214:114487. doi: 10.1016/j.bios.2022.114487. Epub 2022 Jun 18.

Abstract

Non-invasive methods of detecting cancer by circulating exosomes are challenged by inefficient purification and identification. This study hereby proposed an automated centrifugal microfluidic disc system combined with functionalized membranes (Exo-CMDS) to isolate and enrich exosomes, which will then be processed by a novel aptamer fluorescence system (Exo-AFS) in order to detect the exosome surface proteins in an effective manner. Exo-CMDS features in highly qualified yields with optimal exosomal concentration of 5.1 × 10 particles/mL from trace amount of blood samples (<300 μL) in only 8 min, which truly accomplishes the exosome isolation and purification in one-step methods. Meanwhile, the limit of detection (LOD) of PD-L1 in Exo-AFS reaches as low as 1.58 × 10 particles/mL. In the trial of clinical samples, the diagnostic accuracy of lung cancer achieves 91% (95% CI: 79%-96%) in contrast to the exosome ELISA (area under the curve: 0.9378 versus 0.8733; 30 patients). Exo-CMDS and Exo-AFS display the precedence in the aspects of inexpensiveness, celerity, purity, sensitivity and specificity when compared with the traditional techniques. Such assays potentially grant a practicable way of detecting inchoate cancers and guiding immunotherapy in clinic.

摘要

通过循环外泌体检测癌症的非侵入性方法受到低效的纯化和鉴定的挑战。本研究提出了一种自动化离心微流控盘系统与功能化膜(Exo-CMDS)相结合,用于分离和富集外泌体,然后通过新型适体荧光系统(Exo-AFS)进行处理,以有效地检测外泌体表面蛋白。Exo-CMDS 具有优异的产率,从痕量 (<300μL) 的血液样本中仅 8 分钟即可获得最佳的外泌体浓度 5.1×10 颗粒/mL,真正实现了一步法的外泌体分离和纯化。同时,Exo-AFS 中 PD-L1 的检测限 (LOD) 低至 1.58×10 颗粒/mL。在临床样本的试验中,与外泌体 ELISA 相比,肺癌的诊断准确率达到 91%(95% CI:79%-96%)(30 例患者)。与传统技术相比,Exo-CMDS 和 Exo-AFS 在经济性、快速性、纯度、灵敏度和特异性方面具有优势。这些检测方法为临床上早期癌症的检测和免疫治疗提供了一种可行的方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验